Nadeem Riaz
@xrtGenomics
Followers
2K
Following
16K
Media
75
Statuses
2K
Physician/Scientist. Head and Neck Oncologist (radiation) & Computational Biologist. Interests in cancer genomics, immunotherapy & DNA repair. @MSKCancerCenter
New York, NY
Joined May 2009
🧵 Paradigm-buster just out: ATM-deficient tumors stay cold ❄️—unlike other DNA-repair defects—so PD-1 blockade alone (or with ATRi) falls flat. We mapped the biology in mice + patients. Paper in @JITCancer now (link below) -- #ImmunoOncology #DNArepair @OncoAlert (1/9).
4
14
44
RT @simocristea: This R packages can transform any plot using color pallets from painting at the Museum of Modern Art in New York. https:/….
0
43
0
How well does AI based assessment of mutations in DNA repair genes in cancer work -- we took a look 👇 great work by @ShuYazaki and team.
1/ 🧬Our paper is out @JCOPO_ASCO!.We tested AlphaMissense(an AI tool for predicting the pathogenicity of missense mutations), across DNA damage repair genes in cancer. Key finding: accuracy varies dramatically by gene .- crucial for clinical use!.➡️
0
3
10
RT @SashaGusevPosts: Oof. Polygenic scores for IQ lose 75% of their explained variance when adding family controls, even worse than the att….
0
267
0
RT @safaviaa: In @JCO_ASCO, our reflections on the timely ASCO TORS guideline @imrtlee @xrtGenomics . 💡Encourage MR (r/o T4+ENE) & PET (r/o….
0
8
0
RT @safaviaa: Led by Drs. Zakeri & @imrtlee, we report early @MSK_RadOnc exp w/ 40 Gy ENI + CCRT for larynx, HPX, p16- OPX + CUP, 97.3% pla….
0
12
0
RT @emollick: 👀Using an autonomous agent based on o3-mini and GPT-4.1, a team from Harvard, MIT & other institutions reproduced and updated….
0
359
0
RT @Jdcramer: What changed in E3311 long-term data?. ✔️Transoral surgery + 50 Gy = durable control in intermediate-risk HPV+ OPC. ✔️No OS o….
0
3
0
AI-based tumor board! This space is evolving so fast. this is a great paper on whats about to come very soon, and very widely. .
Very happy to share our new paper on LLM-based tumor board agents. Submitted August 2024, published in @NatureCancer today ☺️ Led by @Dykex6
0
0
3
RT @Aiims1742: Funny how two of the more interesting pieces of data at #ASCO25 have little to do with extraneous medications per se, but ra….
0
66
0
RT @CJTsaiMDPhD: 👋🚨NIVOPOSTOP GORTEC #ASCO25. ‼️adj nivo x1 ➡️concurrent nivo-CRT➡️ nivo improved DFS (mostly LRC). Waiting for OS results.….
0
12
0
RT @CJTsaiMDPhD: 🔔Exciting results of adj cancer directed vaccines for high risk respected HPVneg HNSCC. #ASCO25 .Congrats to the investiga….
0
4
0
RT @CJTsaiMDPhD: Remarkable efforts to obtain on-treatment tissue to study TME. CRT with sequential pembro *might* be more favorable than c….
0
14
0
Interesting data on some exceptional respones to Lu-PSMA in ATM-mutated cancers. In line with EBRT data.
Stunning research from @EdmondMKwan on ctDNA in theranostics:.🧬Low ctDNA predicts better response with ¹⁷⁷Lu-PSMA-617 vs. cabazitaxel chemotherapy.⚠️PTEN alterations linked to worse outcomes on cabazitaxel.🧪ATM defects tied to favorable PSMA-617 results.🩻PET quantitative
0
2
12
RT @HenningWillers: 📢Safety and potential efficacy of PARP inhibitor with #radiotherapy in homologous recombination defective triple negati….
0
4
0
RT @jitcancer: New #JITC article: The cold immunological landscape of ATM-deficient cancers @isaacpei @deadoc80 @xr….
0
2
0
RT @AvanGupta: So excited to share our latest work with Sarat Chandarlapaty, @antoniomarraMD, Andrea Gazzo @MSKCancerCenter out today in @N….
0
16
0
RT @MSKCancerCenter: We're excited to share that Dr. Andy Minn will return to MSK as the inaugural Chair of MSK’s new Immuno-Oncology Progr….
0
19
0
RT @SeanPitroda: Excited to share our recent @Nature paper!. Tremendous collaborative effort from @UCCancerCenter….
0
43
0